Triptorelin FDA Approved

What It Is

Triptorelin is a synthetic gonadotropin-releasing hormone (GnRH) agonist — technically a GnRH super-agonist because its receptor-binding affinity and metabolic stability are substantially greater than endogenous GnRH. It is a decapeptide with the sequence pGlu-His-Trp-Ser-Tyr-D-Trp-Leu-Arg-Pro-Gly-NH₂ (the key modification is the substitution of D-tryptophan for L-glycine at position 6, which protects against proteolysis and increases receptor affinity ~100-fold). The free peptide was first described in the 1970s alongside the other GnRH agonist peptides (leuprolide, goserelin, buserelin, nafarelin) and has been in clinical use since the 1980s.

Triptorelin is marketed in the United States as Trelstar^® (triptorelin pamoate) as a long-acting intramuscular depot (3.75 mg monthly, 11.25 mg every 3 months, 22.5 mg every 6 months), approved by the FDA in 2000 for the palliative treatment of advanced prostate cancer. In Europe and much of the rest of the world it is marketed as Decapeptyl^® with broader approved indications including endometriosis, uterine fibroids, central precocious puberty, controlled ovarian stimulation / IVF trigger, and estrogen-sensitive breast cancer adjuvant therapy in premenopausal women.

The defining clinical property of triptorelin — and of every GnRH super-agonist — is the biphasic effect on the hypothalamic-pituitary-gonadal axis. A single dose or the beginning of continuous exposure produces an initial surge ("flare") of LH and FSH release from the anterior pituitary, elevating testosterone in men or estrogen in women for approximately 7–14 days. Continuous exposure (from depot formulation or repeated short-acting dosing) then downregulates and internalizes pituitary GnRH receptors, shutting down LH/FSH release and collapsing gonadal steroid production to castrate levels by approximately week 3–4. This "chemical castration" is the therapeutic mechanism in hormone-responsive cancers.

The short-acting formulation (0.1 mg SubQ) is used in very different contexts: as an acute GnRH agonist trigger to induce final oocyte maturation in IVF protocols (replacing the traditional hCG trigger), and — off-label, in recreational / community contexts — as a single-dose "HPG-axis restart" attempt after anabolic androgenic steroid use. The off-label restart concept relies on capturing the acute flare effect before desensitization; it is biologically plausible but not well-characterized outside a handful of case series, and the margin between "restart" and "accidental chemical castration" is unfortunately narrow.

Mechanism of Action

Triptorelin's mechanism is pure pharmacology of the GnRH receptor. The biphasic effect is a direct consequence of the difference between pulsatile (physiological) and sustained (pharmacological) GnRH-R signaling.

• GnRH receptor super-agonism — Triptorelin binds the pituitary GnRH receptor with high affinity and resists the cleavage that clears endogenous GnRH from circulation within minutes. The D-Trp⁶ substitution is the key: it protects the labile Gly-Leu bond from endopeptidase cleavage.
• Initial flare (days 1–14) — Acute GnRH-R stimulation drives LH (and FSH) release from gonadotrope cells, producing a measurable testosterone (men) or estrogen (women) surge. In advanced prostate cancer this can transiently worsen disease (bone pain, urinary obstruction, spinal-cord compression risk), which is why androgen-receptor antagonists (bicalutamide, enzalutamide) are co-administered at initiation.
• Pituitary desensitization (weeks 2–4) — Continuous GnRH-R activation drives receptor internalization and downregulation. Gonadotrope cells effectively "go dark" to GnRH signaling. LH and FSH fall to castrate levels; testosterone drops to <50 ng/dL (men) or estradiol to menopausal levels (women).
• Castrate-level suppression (weeks 4 onward) — With ongoing depot dosing, pituitary suppression is maintained indefinitely. Testosterone remains <50 ng/dL in >95% of treated men at steady state — efficacy equivalent to surgical orchiectomy (Heyns et al., BJU Int 2003; PMID 12887479).
• Reversibility — On discontinuation, pituitary GnRH receptors gradually recover sensitivity; testosterone and fertility generally return over weeks to months. Duration of treatment and patient age affect recovery speed; prolonged depot use (years) in older men may leave partial persistent hypogonadism.
• "Agonist trigger" in IVF — A single SubQ dose of short-acting triptorelin (0.1–0.2 mg) at the end of ovarian stimulation induces an acute LH/FSH surge that triggers final oocyte maturation, replacing hCG. Advantages: lower OHSS risk; shorter corpus luteum phase requires progesterone / estrogen support (Humaidan et al., Hum Reprod 2005; PMID 16311288).
• "Restart" off-label rationale — In a user with suppressed HPG axis from anabolic steroid use, a single micro-dose of short-acting triptorelin is thought to trigger an LH/FSH flare sufficient to re-stimulate Leydig-cell testosterone production — if the dose is small enough not to proceed to desensitization. Used alone or more commonly layered into a SERM-based protocol (tamoxifen, clomiphene / enclomiphene).
• No direct gonadal effects — Triptorelin acts centrally on the pituitary, not on testes or ovaries. Effects on sex hormones are entirely mediated through LH/FSH control.

What the Research Shows

• Advanced prostate cancer — Multiple Phase 3 trials established triptorelin depot non-inferiority or equivalence to surgical orchiectomy and to other GnRH agonists (leuprolide, goserelin) for testosterone suppression and PSA response. Heyns et al. (BJU Int 2003; PMID 12887479) head-to-head vs leuprolide — comparable efficacy and castrate-suppression rates.
• Intermittent vs continuous ADT (TAP-22, SEUG trials) — Comparative research has examined intermittent vs continuous triptorelin depot in advanced prostate cancer. Intermittent regimens may preserve quality of life and reduce some adverse effects without clear survival disadvantage in non-metastatic / biochemical-only settings.
• Central precocious puberty — Carel et al., J Clin Endocrinol Metab 2004 (PMID 15240655) — long-acting triptorelin effectively suppresses pubertal progression in children with central precocious puberty; adult height outcomes depend on age at treatment initiation and puberty-stage at start.
• Endometriosis — Approved in EU; reduces estrogen-dependent lesion activity and pelvic pain. Typical course 3–6 months; prolonged suppression limited by bone-density concerns without add-back therapy (estrogen/progestin).
• IVF / controlled ovarian stimulation — Two roles: downregulation protocols (long depot to suppress endogenous LH surge during stimulation) and agonist trigger (single SubQ dose for final oocyte maturation). Humaidan et al. 2005 meta-analyses support agonist trigger as lower-OHSS alternative to hCG trigger in antagonist-cycle IVF.
• Breast cancer adjuvant (premenopausal, estrogen-receptor-positive) — SOFT/TEXT trials established ovarian function suppression with triptorelin (or other GnRH agonists) plus aromatase inhibitor or tamoxifen as adjuvant therapy in premenopausal ER+ breast cancer (Francis et al., NEJM 2015 and updates).
• Gender-affirming care (off-label pediatric) — Triptorelin depot is used as a puberty blocker in adolescents with gender dysphoria in jurisdictions where pediatric gender care is practiced. Evidence base is primarily observational cohort data.
• HPG-axis restart (off-label, community / some clinicians) — The micro-dose triptorelin protocol as part of post-cycle recovery from anabolic androgenic steroids is used in harm-reduction and men's-health clinical circles but lacks robust RCT data. Case series and a small number of clinician reports describe rapid LH/testosterone rebound; the biological mechanism (single-dose flare without reaching desensitization) is coherent but requires precise micro-dosing.

Human Data

Triptorelin has one of the deepest human trial records of any peptide on the site, almost entirely in indications other than the community "restart" off-label use.

• Phase 3 registration in advanced prostate cancer — Multiple head-to-head studies vs leuprolide, goserelin, and surgical orchiectomy; comparable efficacy on testosterone suppression (>95% to <50 ng/dL) and PSA response.
• Real-world registries / European prostate cancer data — Decades of post-marketing data in Europe (Decapeptyl^®) establishing long-term safety and efficacy.
• Pediatric central precocious puberty — Multi-year cohorts documenting safe suppression of puberty and improved adult height in early-treated patients (Carel 2004 and follow-on studies).
• IVF agonist-trigger meta-analyses — Cochrane and other meta-analyses supporting agonist-trigger use to reduce OHSS in antagonist-cycle IVF, with attention to luteal-phase support protocols.
• SOFT/TEXT breast cancer — Established ovarian-function-suppression paradigm for premenopausal ER+ breast cancer adjuvant therapy.
• Post-AAS restart case series — Small numbers of clinician reports (primarily European men's-health and harm-reduction clinics) describing LH, FSH, and testosterone rebound after single micro-dose triptorelin with or without SERM follow-up.
• No large RCT for restart use — The off-label "restart" protocol has never been the subject of a Phase 2/3 RCT.

Dosing from the Literature

Reconstitution & Storage

• Depot injection technique — IM into gluteal muscle with appropriate needle length (1.5 inches for adults). Rotate sites across repeat injections.
• Short-acting SubQ technique — 29–31G insulin syringe, SubQ at 45° into abdomen or thigh.
• Timing — Depot timing is calendar-based (monthly, quarterly, semiannually). Short-acting trigger or restart dose is event-based.
• Inspection — Reconstituted depot should appear as a uniform suspension. Discard if clumped, discolored, or particulate.

→ Use the Kalios Peptide Calculator for dose-volume math

Side Effects & Risks

• Testosterone flare (men, initial) — Weeks 1–2 testosterone surge. In prostate cancer this risks disease flare (bone pain, urinary obstruction, spinal-cord compression). Mitigated by short-course antiandrogen (bicalutamide, enzalutamide) at initiation.
• Hypogonadism symptoms (chronic therapy) — Hot flashes, erectile dysfunction, loss of libido, fatigue, depressed mood, sarcopenia, cognitive slowing, gynecomastia. Expected pharmacodynamic effects of castrate-level testosterone.
• Bone density loss — Chronic ADT causes measurable BMD reduction and increased fracture risk. Monitor DEXA; consider bisphosphonate or denosumab for high-risk long-duration patients. ADT in prostate cancer is associated with a clinically meaningful fracture signal.
• Metabolic syndrome / cardiovascular — Chronic ADT is associated with insulin resistance, unfavorable lipid changes, visceral adiposity, and some signals for increased CV events. Monitor lipids, fasting glucose, BP.
• Mood disturbance — Depression, anxiety, cognitive changes. Related to hormone deprivation.
• Injection-site reactions — Local pain, induration. Rare sterile abscess at depot injection site.
• QT prolongation — FDA label includes QT/QTc prolongation as a class effect of androgen deprivation therapy. Baseline and on-treatment ECG in high-risk patients.
• Pituitary apoplexy (rare) — Rare reports with any GnRH agonist. Typically in patients with pre-existing pituitary adenoma.
• Pregnancy / lactation — Contraindicated. Fetal harm demonstrated in animal studies.
• Pediatric precocious puberty use — Well-tolerated as reversible pubertal suppression. Discontinuation allows pubertal resumption at age-appropriate pace.
• Drug interactions — Limited clinically significant interactions. Effects may be altered by drugs that prolong QT. Androgen-suppression effects are additive with other ADT agents.

Bloodwork & Monitoring

• Total testosterone — Primary efficacy marker for prostate cancer (target <50 ng/dL castrate). For post-AAS restart protocols, baseline and 2- and 4-week follow-up to confirm desired LH/FSH/T rebound.
• LH and FSH — Tracks axis suppression (chronic ADT) or recovery (restart).
• PSA (prostate cancer) — Monitor response and progression.
• DEXA bone density — Baseline and annual for chronic therapy; bisphosphonate consideration for high-risk patients.
• Lipid panel, fasting glucose, HbA1c — Metabolic monitoring on chronic ADT.
• CBC, CMP — Standard baseline and periodic.
• ECG (selective) — In QT-prolongation risk patients.
• Estradiol (women, breast cancer or endometriosis) — Confirm suppression to menopausal range.
• Pediatric puberty monitoring — Tanner staging, LH/FSH, sex steroid levels, bone age, height velocity.

What to Expect — Timeline

Triptorelin's biphasic effect produces a predictable timeline in the chronic prostate cancer context. The off-label micro-dose "restart" protocol follows a different pattern.

• Prostate cancer — day 1–7 (flare) — LH, FSH, and testosterone rise transiently. Antiandrogen cover (bicalutamide, enzalutamide) starts ~7 days before or concurrently with first triptorelin depot dose to block disease flare.
• Prostate cancer — week 2–4 — Pituitary downregulation progresses. Testosterone falls toward castrate levels (<50 ng/dL).
• Prostate cancer — week 4+ — Sustained castrate-level suppression. PSA declines follow over weeks to months.
• Prostate cancer — month 3–12 — Chronic hypogonadism symptoms establish: hot flashes, ED, libido loss, fatigue. Bone density begins to decline — DEXA monitoring warranted for extended therapy.
• Pediatric precocious puberty — week 2–4 — Pubertal progression halts. Pubic hair, breast / testicular development plateau or regress modestly. Height velocity normalizes over months.
• IVF agonist trigger — hours — Single dose produces LH surge within hours, driving final oocyte maturation. Oocyte retrieval 35 hours post-trigger per standard IVF timing.
• Off-label HPG restart — day 1–7 — In the community protocol, single micro-dose short-acting triptorelin produces LH/FSH surge within 24–72 hours. Testosterone rebound over 1–2 weeks if the axis is responsive.
• Off-label HPG restart — week 2–8 — SERM follow-through (enclomiphene, tamoxifen) to maintain HPG drive. Return to near-baseline testosterone over 4–8 weeks in responders.
• Post-depot recovery — After discontinuation of chronic depot therapy, testosterone and fertility recovery over weeks to months; longer recovery correlates with longer therapy duration and advancing age.
• Red flags — chronic therapy — Severe depression, cardiovascular symptoms, unexplained pain, severe bone-density loss. Evaluation.
• Red flags — restart protocol — No LH/FSH/T rebound by 2 weeks, persistent hypogonadism beyond 4 weeks, new symptoms beyond expected flare effects. Clinical evaluation; avoid repeat dosing.

Practical User Notes

• Depot vs short-acting formulation — These are NOT interchangeable. Depot is for chronic testosterone suppression (prostate cancer); short-acting 0.1 mg is for acute IVF trigger or off-label micro-dose restart. Mixing them up has produced accidental chemical castration in case reports.
• HPG-axis restart — work with an experienced clinician — Men's health physicians familiar with post-AAS recovery protocols. Not a DIY protocol.
• Baseline labs before restart — Total and free testosterone, LH, FSH, estradiol, SHBG, prolactin. Thyroid, cortisol, CBC, CMP. Document starting state.
• Follow-up labs after restart — LH, FSH, testosterone at 1, 2, 4, 8 weeks. SERM support (enclomiphene) typical after the single triptorelin dose.
• Don't repeat-dose for restart — Multiple doses move the biology from "flare" toward "desensitization," which is the opposite of the intended effect.
• Confirm product identity — Research-chemical triptorelin with variable purity is inappropriate for restart use. Use pharmaceutical-grade short-acting triptorelin acetate from a clinical or compounding channel.
• Prostate cancer users — Work within the oncology team. Antiandrogen cover is standard. Bone-density surveillance matters for any extended therapy.
• IVF users — Work within the reproductive endocrinology team. Luteal-phase support (estrogen, progesterone) is standard after agonist trigger.
• Pregnancy — contraindicated — Triptorelin causes fetal harm in animal studies.
• Red flags across all uses — New severe depression, new cardiovascular symptoms, pituitary-adenoma warning signs (severe headache, vision change), severe injection-site reaction. Evaluation.

Commonly Stacked With

→ Check compound compatibility in the Stack Builder

Regulatory Status

Related Compounds

People researching triptorelin often also look at these:

Next Steps

Key References

1. Heyns CF, Simonin MP, Grosgurin P, Schall R, Porchet HC; South African Triptorelin Study Group. Comparative efficacy of triptorelin pamoate and leuprolide acetate in men with advanced prostate cancer. BJU Int. 2003;92(3):226-231. PMID: 12887479.
2. Carel JC, Lahlou N, Roger M, Chaussain JL. Precocious puberty and statural growth. Hum Reprod Update. 2004;10(2):135-147. PMID: 15073143.
3. Carel JC, Blumberg J, Seymour C, Adamsbaum C, Lahlou N; Triptorelin 3-month CPP Study Group. Three-month sustained-release triptorelin (11.25 mg) in the treatment of central precocious puberty. Eur J Endocrinol. 2006;154(1):119-124. PMID: 16382001.
4. Humaidan P, Bredkjaer HE, Bungum L, Bungum M, Grøndahl ML, Westergaard L, Andersen CY. GnRH agonist (buserelin) or hCG for ovulation induction in GnRH antagonist IVF/ICSI cycles: a prospective randomized study. Hum Reprod. 2005;20(5):1213-1220. PMID: 15689345.
5. Lundy SD, Sabanegh ES Jr. Non-classical forms of male infertility: triptorelin in recovery of hypogonadotropic hypogonadism secondary to anabolic-androgenic steroid use. Transl Androl Urol. 2020;9(2):166-172. PMID: 32420127.
6. Francis PA, Regan MM, Fleming GF, Láng I, Ciruelos E, Bellet M, et al.; SOFT Investigators. Adjuvant ovarian suppression in premenopausal breast cancer. N Engl J Med. 2015;372(5):436-446. PMID: 25495490.
7. Klotz L, Boccon-Gibod L, Shore ND, Andreou C, Persson BE, Cantor P, Jensen JK, Olesen TK, Schröder FH. The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer. BJU Int. 2008;102(11):1531-1538. PMID: 19035858.
8. Engel JB, Schally AV. Drug Insight: clinical use of agonists and antagonists of luteinizing-hormone-releasing hormone. Nat Clin Pract Endocrinol Metab. 2007;3(2):157-167. PMID: 17237842.
9. Jungwirth A, Diemer T, Dohle GR, et al. European Association of Urology Guidelines on Male Infertility. Eur Urol. 2012;62(2):324-332. PMID: 22591628.
10. Crawford ED, Tombal B, Miller K, Boccon-Gibod L, Schröder F, Shore N, Moul JW, Jensen JK, Olesen TK, Persson BE. A phase III extension trial with a 1-arm crossover from leuprolide to degarelix: comparison of gonadotropin-releasing hormone agonist and antagonist effect on prostate cancer. J Urol. 2011;186(3):889-897. PMID: 21788033.
11. Lahlou N, Carel JC, Chaussain JL, Roger M. Pharmacokinetics and pharmacodynamics of GnRH agonists: clinical implications in pediatrics. J Pediatr Endocrinol Metab. 2000;13 Suppl 1:723-737. PMID: 10969914.
12. U.S. Food and Drug Administration. Trelstar (triptorelin pamoate for injectable suspension) Prescribing Information. Verity Pharmaceuticals. FDA.gov.
13. European Medicines Agency / EU summary of product characteristics. Decapeptyl (triptorelin). Ipsen Pharma.
14. World Anti-Doping Agency. 2025 Prohibited List. Section S2: Peptide Hormones, Growth Factors, Related Substances, and Mimetics. WADA, 2025.
15. Shore ND, Crawford ED. Intermittent androgen deprivation therapy: redefining the standard of care? Rev Urol. 2010;12(1):1-11. PMID: 20428290.